Los Angeles Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Los Angeles Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.32K	Hold	463	–	–	﹤0.01%	2004
2026 Q1	$10.1K	Hold	463	–	–	﹤0.01%	1953
2025 Q4	$10.8K	Buy	+463	New	+$9.76K	﹤0.01%	2053
2021 Q1	–	Sell	-68,539	Closed	-$11.7M	–	1648
2020 Q4	$11.7M	Sell	68,539 -53,276	-44%	-$7.89M	0.05%	258
2020 Q3	$17.1M	Sell	121,815 -7,552	-6%	-$1.15M	0.08%	185
2020 Q2	$20.7M	Buy	129,367 +42,523	+49%	+$5.79M	0.1%	188
2020 Q1	$8.49M	Buy	+86,844	New	+$9.93M	0.05%	265
2019 Q2	–	Sell	-2,180	Closed	-$260K	–	1416
2019 Q1	$260K	Buy	+2,180	New	+$280K	﹤0.01%	1238
2018 Q2	–	Sell	-10,620	Closed	-$787K	–	1491
2018 Q1	$787K	Buy	+10,620	New	+$708K	﹤0.01%	896

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Los Angeles Capital Management's SRPT Position: Q2 2026 in Review

Los Angeles Capital Management held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 463 shares worth $8.32K. The position accounts for ﹤0.01% of the portfolio, ranked #2004.

Los Angeles Capital Management first reported a position in SRPT in Q1 2018 and has held it in 9 quarters since. The position peaked at $20.7M in Q2 2020. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Los Angeles Capital Management held 463 shares of Sarepta Therapeutics worth $8.32K as of Q2 2026.
Los Angeles Capital Management left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #2004 holding.
Los Angeles Capital Management first reported a position in Sarepta Therapeutics in Q1 2018 and has held it in 9 quarters since.
Los Angeles Capital Management's Sarepta Therapeutics position peaked at $20.7M in Q2 2020.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.